BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Mitigate Short- and Long-Term Effects of mTBI
Oct 17, 2022
Odyssey Health (OTC: ODYY) early last year acquired PRV-002, a drug candidate for concussed patients to mitigate both short-term and long-term consequences of concussion. Concussion or mTBI “is caused by a jolt, blow or force to the head that changes the brain’s function. This change often results in myriad consequences ranging from emotional and somatic changes to cognitive impairment and physical symptoms… In most cases, concussion symptoms resolve within a few days or weeks as the damaged pathways rebuild and strengthen through repetition, use and cleanup of cell debris. However, there has been growing concern that mTBI may be associated with long-term consequences, particularly due to repeated or multiple head impacts,” explains a recent article. “Odyssey has so far evidenced, through animal studies, that PRV-002 can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation caused by concussion while simultaneously restoring proper blood flow. The drug is intended to be administered immediately after a concussive episode, effectively mitigating the effects a blow or jolt might have on the brain and its functions.”
To view the full article, visit https://ibn.fm/HSL5L
About Odyssey Health Inc.
Odyssey Health is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information about the company, visit www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
More News
Rivian C.E.O. RJ Scaringe Has Some Ideas for How to Make More Cars in America
RJ Scaringe thinks it will take robots, tariffs and diplomacy to maintain a manufacturing base in the United States.
Mistakes? We’ve Made a Few
For most of its life, The New York Times has tried to correct its errors. These efforts have not always been perfect.
As the Rich Buy Bigger Boats, Private Equity Is Investing in the Booming Marina Business
The private equity firm Blackstone now owns more marinas than anyone in the world.
Families missing out on NHS money for healthy food
Figures show as few as 64% of eligible families are claiming NHS money to buy milk, fruit and veg.
CNN, MS NOW and Politico Barred From White House After Trump’s Ban
The prohibition on certain journalists was a major escalation in President Trump’s war on the media, and will probably face a legal challenge.
Trump says he plans to form AI Force, appoint AI 'Czar'
US President Donald Trump said Saturday that he is forming an "AI Force" and will announce an "AI Czar" in the near future.
Not all AI workers think the tech could kill everyone
In text exchanges and conversations, multiple people who have worked for leading companies are sceptical of the warnings.
California Cracks Down on Influencers’ Undisclosed Political Ads
Under a new law, creators could face fines of $5,000 per post if they don’t disclose that they were paid to make political content.
Converse Removes Ad That Drew Comparisons to K.K.K. Imagery
“This should not have happened and we will do better,” said Converse, which apologized for the ad. Critics said it depicted a Ku Klux Klan robe and a lynching.
India Is Again Squeezed Between the Threat of Trump Tariffs and Russian Oil
India is trying to secure affordable energy while preserving a crucial relationship with Washington, a balancing act made harder by turmoil in global energy markets.
Amodei, Anthropic’s Leader, Exposed A.I.’s Dangers. It’s Time to Act.
The Times columnist Kevin Roose sees reasons for optimism — and worry — as the world wakes up to what Silicon Valley has been talking about for years.
At DraftKings, AI Targets the Gamblers Likeliest to Lose
Data science helps determine who receives betting incentives, but the company has resisted using similar technology to protect gamblers at risk of addiction.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.